表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的研究进展
DOI: 10.3971/j.issn.1000-8578.2016.04.013
Keywords: A Meta-analysis,NSCLC的疫苗治疗研究进展,Effect of Operation Incision Selection on Success rate of Sentinel Lymph Node Biopsy and Subcutaneous Hydrops in Breast Cancer,Effect of Vascular Endothelial Cadherin on Invasion and Metastasis of Non-small Cell Lung Cancer Cells and Related Mechanism,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Radiotherapy,Quality Assessment of Reports of Randomized Controlled Trials Published in Chinese in Field of Non-small Cell Lung Cancer in China,A Prospective Clinical Trial of Treatment Models on Malignant Ovarian Germ Cell Tumor Patients,Evaluation of Ligand-targeted PCR Method in Detecting Tumor Cell Levels in Pleural Effusion of Patients with Non-small Cell Lung Cancer,Association of Cytochrome P450 2E1-1239G>C Genetic Variation with Prognosis of Metastatic Non-small Cell Lung Cancer Patients,Prognostic Value of Serum CEA, CA125 and Cyfra21-1 in Patients with Advanced Nonsmall Cell Lung Cancer,Clinical Characteristics and Treatment Methods on Peripheral Primitive Neuroectodermal Tumors Patients
Abstract:
摘要 表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKI）在晚期EGFR突变阳性的非小细胞肺癌（non-small cell lung cancer, NSCLC）患者中的疗效肯定，但EGFR-TKI能否提高完全切除的NSCLC术后辅助治疗疗效不确切。部分研究发现在可切除的Ⅰ~Ⅲ期EGFR敏感突变肺腺癌患者中，辅助TKI治疗有使无疾病生存（disease free survival,DFS）获益的趋势，另一部分临床研究未能证实EGFR-TKI在术后辅助治疗有获益。造成各研究结果不一的原因很多，如人群选择、EGFR-TKI使用时长、耐药等。国内外目前一些设计比较合理的，对比EGFR-TKI化疗辅助治疗Ⅱ~ⅢA期EGFR敏感突变的NSCLC临床研究正在进行，值得期待。目前，早期NSCLC术后TKI辅助治疗仅限于临床试验，不建议作为临床常规治疗
Full-Text
